1
|
Sengupta AK, Gunda A, Malpani S, Serkad CPV, Basavaraj C, Bapat A, Bakre MM. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX. Cancer Med 2020; 9:7810-7818. [PMID: 33027559 PMCID: PMC7643688 DOI: 10.1002/cam4.3495] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 08/08/2020] [Accepted: 09/10/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND CanAssist Breast (CAB) is a prognostic test for early stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer patients, validated on Indian and Caucasian patients. The 21-gene signature Oncotype DX (ODX) is the most widely used commercially available breast cancer prognostic test. In the current study, risk stratification of CAB is compared with that done with ODX along with the respective outcomes of these patients. METHODS A cohort of 109 early stage breast cancer patients who had previously taken the ODX test were retested with CAB, and the results respectively compared with old cut-offs of ODX as well as cut-offs suggested by TAILORx, a prospective randomized trial of ODX. Distant metastasis-free survival after 5 years was taken as the end point. RESULTS CanAssist Breast stratified 83.5% of the cohort into low-risk and 16.5% into high-risk. With the TAILORx cut-offs, ODX stratified the cohort into 89.9% low-risk and 10.1% into high-risk. The low, intermediate, and high-risk groups with ODX old cut-offs were 62.4%, 31.2%, and 6.4%, respectively. The overall concordance of CAB with ODX using both cut-offs is 75%-76%, with ~82%-83% concordance in the low-risk category of these tests. The NPV of the low-risk category of CAB was 93.4%, and of ODX with TAILORx cut-offs was 91.8% and 89.7% with old cut-offs. CONCLUSIONS Compared to the concordance reported for other tests, CAB shows high concordance with ODX, and in addition shows comparable performance in the patient outcomes in this cohort. CAB is thus an excellent and cost-effective alternative to ODX.
Collapse
|
2
|
Patil P, Bakre MM, Basavaraj C, Malpani S, Gunda A, Prakash C, Somashekhar S. CanAssist breast: An affordable breast cancer prognostic test validated on Asian patients. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
541 Background: Treatment decisions for early stage HR+/HER2neu- breast cancer patients in the West routinely depend on prognostic tests that predict risk of recurrence. However, such tests are rarely used in Asia due to prohibitive costs and lack of validation data on Asian patients. Chemotherapy is thus often a default treatment leading to physiological and financial toxicity. To address these, we have developed CanAssist Breast (CAB) as an affordable IHC-based prognostic test, retrospectively validated on ~1400 patients, 63% South Asians and rest Caucasians. To date CAB has been prescribed by 180+ doctors across 30 cities in India for ~600 patients in clinics, enabling personalized treatment decisions. Methods: Primary surgical FFPE blocks and clinical follow-up data were obtained from hospitals. GraphPad Prism and MedCalc were respectively used for Kaplan-Meier survival analyses and Cox logistic regression to calculate hazard ratios. Results: The median age of diagnosis in the validation cohort was 56 years, 63% patients with stage II disease and 60% node negative tumors. Distant Metastasis Free Survival (DMFS) in the low-risk category of the validation cohort was 95%, and 84% in high-risk (P < 0.0001). Similar results were obtained with the Caucasian subgroup, as also with the chemotherapy-naive subgroup (30% of the cohort), demonstrating that risk stratification by CAB is unaffected by race or chemotherapy. Next, the performance of CAB was compared with Oncotype DX (ODX). 83% patients stratified as low risk by ODX (RS 0-25) in a sub-cohort of 109 were also stratified as low-risk by CAB. To assess the impact of CAB in treatment decision making, we assessed the data of 589 patients who have undergone CAB testing so far, 288 were identified as low-risk. 93% of these CAB low-risk patients were not given chemotherapy, demonstrating the clinical impact of CAB. Conclusions: CAB is the first test of its kind to be retrospectively validated in Asia. It shows high concordance with ODX in risk stratification of patients. CAB has been in clinical practice in India and near-India markets for 2 years and is helping clinicians and patients in making affordable treatment decisions.
Collapse
|
3
|
Ramkumar C, Buturovic L, Malpani S, Kumar Attuluri A, Basavaraj C, Prakash C, Madhav L, Doval DC, Mehta A, Bakre MM. Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. Biomark Insights 2018; 13:1177271918789100. [PMID: 30083053 PMCID: PMC6066801 DOI: 10.1177/1177271918789100] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 06/26/2018] [Indexed: 01/13/2023] Open
Abstract
Use of proteomic strategies to identify a risk classifier that estimates probability of distant recurrence in early-stage hormone receptor (HR)-positive breast cancer is relevant to physiological cellular function and therefore to intrinsic tumor biology. We used a 298-sample retrospective training set to develop an immunohistochemistry-based novel risk classifier called CanAssist-Breast (CAB) which combines 5 prognostically relevant biomarkers and 3 clinico-pathological parameters to arrive at probability of distant recurrence within 5 years from diagnosis. Five selected biomarkers, namely, CD44, ABCC4, ABCC11, N-cadherin, and pan-cadherin, were chosen based on their role in tumor metastasis. The chosen biomarkers represent the hallmarks of cancer and are distinct from other proliferation and gene expression-based prognostic signatures. The 3 clinico-pathological parameters integrated into the machine learning-based CAB algorithm are tumor size, tumor grade, and node status. These features are used to calculate a "CAB risk score" that classifies patients into low- or high-risk groups and predicts probability of distant recurrence in 5 years. Independent clinical validation of CAB in a retrospective study comprising 196 patients indicated that distant metastasis-free survival (DMFS) was significantly different in the 2 risk groups. The difference in DMFS between the low- and high-risk categories was 19% in the validation cohort (P = .0002). In multivariate analysis, CAB risk score was the most significant independent predictor of distant recurrence with a hazard ratio of 4.3 (P = .0003). CanAssist-Breast is a precise and unique machine learning-based proteomic risk-classifier that can assist in risk stratification of patients with early-stage HR+ breast cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Dinesh Chandra Doval
- Chair Medical Oncology & Chief of Breast & Thoracic Services, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - Anurag Mehta
- Director Department of Laboratory & Transfusion Services and Director Research, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | | |
Collapse
|
4
|
SP S, Bakre MM, Ramkumar C, Basavaraj C, Attuluri A, Madhav L, Prakash C, Naidu N, Malpani S. Abstract P3-08-10: Development and validation of a broad-based second generation multi marker “Morphometric IHC” test for optimal treatment planning of stage 1 and 2 breast cancer patients in low resource settings. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aims:
Assessment of 'risk of recurrence' in ER+ breast cancer patients based on clinical parameters and existing hormone receptor signaling pathway and/or proliferation based biomarkers is insufficient, leading to treatment of majority of patients with chemotherapy. First generation risk identification tests like OncotypeDx and Mammaprint are not impactful in India and SE Asia as are largely prognostic with limited chemotherapy-predictivity and are prohibitively expensive. A cost-effective 'predictive' test which will accurately estimate the 'risk of recurrence' for a 'broader' (node - & +) set of breast cancer patients in low resource settings is urgently required.
Materials and Methods:
Using a retrospective training cohort of 300 node– and node+ patients, we developed 'CanAssist-Breast'- a Morphometric Immunohistochemistry based test comprising 5 biomarkers plus three clinical parameters (Tumor size, grade and node status) to arrive at 'CanAssist-Breast Score'. The risk stratification model was developed using cutting edge support vector based machine learning technology. CanAssist-Breast Score stratifies patients into an all actionable 'low or high' risk for recurrence, with no intermediate zone. CanAssist-Breast biomarkers include cancer stem cell markers, Cadherins, and ATP transporter proteins - all critical players in the various steps of chemotherapy resistance leading to metastasis.
Results:
We validated CanAssist-Breast in accordance with EGAPP recommendations which require that prognostic tests be validated both analytically and clinically prior to being utilized in patients. Analytical validation experiments were performed to assess 'variation' in the outcome prediction due to critical IHC variables. We tested inter-pathologists, sample, operator and laboratory site variation and found high concordance in the outcome predictions across all variables, confirming the robustness and reproducibility of the test.
Extended clinical validation on 1000+ pre and post-menopausal cases shows NPV of 95%. The majority of patients in 'low risk' had Stage 2, Grade 2/3 disease over Stage 1, Grade 1 disease, demonstrating that CanAssist-Breast reclassifies patients who would be considered high risk clinically.
In a head-to-head pilot study of 100 patients with Oncotype Dx, CanAssist-Breast test had about 80% concordance with Oncotype in the 'low risk' category. Importantly, CanAssist-Breast correctly stratified few recurred cases as 'high risk' which were called 'low risk' by Oncotype Dx and thus were not treated with chemotherapy.
Conclusion:
In conclusion, we have developed a robust, accurate and low-cost prognostic test to predict risk of recurrence and enable optimal treatment planning in patients with early stage Breast Cancer.
Citation Format: SP S, Bakre MM, Ramkumar C, Basavaraj C, Attuluri A, Madhav L, Prakash C, Naidu N, Malpani S. Development and validation of a broad-based second generation multi marker “Morphometric IHC” test for optimal treatment planning of stage 1 and 2 breast cancer patients in low resource settings [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-08-10.
Collapse
Affiliation(s)
- S SP
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - MM Bakre
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - C Ramkumar
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - C Basavaraj
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - A Attuluri
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - L Madhav
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - C Prakash
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - N Naidu
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| | - S Malpani
- Manipal Comphrensive Cancer Center, Manipal Hospital, Bangalore, Karnataka, India; OncoStem Diagnostics Pvt Ltd;, Bangalore, Karnataka, India
| |
Collapse
|
5
|
Burdette J, Coppeta J, Isenberg B, Borenstein J, Xiao S, Zhu J, Rashedi A, Kim J, Olalekan S, Getsios S, McKinnon K, Pavone M, Malpani S, Sefton E, Woodruff T. Ex-vivo female reproductive tract integration in a 3D microphysiologic system. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.07.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Pavone M, Kelsh J, Malpani S, Confino R, Jasti S, Briley S, Zhang J, Duncan F. Cytokine antibody array profiling in human follicular fluid as a potential marker for oocyte quality. Fertil Steril 2016. [DOI: 10.1016/j.fertnstert.2016.07.554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Nair CB, Manjula J, Subramani PA, Nagendrappa PB, Manoj MN, Malpani S, Pullela PK, Subbarao PV, Ramamoorthy S, Ghosh SK. Differential Diagnosis of Malaria on Truelab Uno®, a Portable, Real-Time, MicroPCR Device for Point-Of-Care Applications. PLoS One 2016; 11:e0146961. [PMID: 26784111 PMCID: PMC4718663 DOI: 10.1371/journal.pone.0146961] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2015] [Accepted: 12/23/2015] [Indexed: 11/27/2022] Open
Abstract
Background Sensitive and specific detection of malarial parasites is crucial in controlling the significant malaria burden in the developing world. Also important is being able to identify life threatening Plasmodium falciparum malaria quickly and accurately to reduce malaria related mortality. Existing methods such as microscopy and rapid diagnostic tests (RDTs) have major shortcomings. Here, we describe a new real-time PCR-based diagnostic test device at point-of-care service for resource-limited settings. Methods Truenat® Malaria, a chip-based microPCR test, was developed by bigtec Labs, Bangalore, India, for differential identification of Plasmodium falciparum and Plasmodium vivax parasites. The Truenat Malaria tests runs on bigtec’s Truelab Uno® microPCR device, a handheld, battery operated, and easy-to-use real-time microPCR device. The performance of Truenat® Malaria was evaluated versus the WHO nested PCR protocol. The Truenat® Malaria was further evaluated in a triple-blinded study design using a sample panel of 281 specimens created from the clinical samples characterized by expert microscopy and a rapid diagnostic test kit by the National Institute of Malaria Research (NIMR). A comparative evaluation was done on the Truelab Uno® and a commercial real-time PCR system. Results The limit of detection of the Truenat Malaria assay was found to be <5 parasites/μl for both P. falciparum and P. vivax. The Truenat® Malaria test was found to have sensitivity and specificity of 100% each, compared to the WHO nested PCR protocol based on the evaluation of 100 samples. The sensitivity using expert microscopy as the reference standard was determined to be around 99.3% (95% CI: 95.5–99.9) at the species level. Mixed infections were identified more accurately by Truenat Malaria (32 samples identified as mixed) versus expert microscopy and RDTs which detected 4 and 5 mixed samples, respectively. Conclusion The Truenat® Malaria microPCR test is a valuable diagnostic tool and implementation should be considered not only for malaria diagnosis but also for active surveillance and epidemiological intervention.
Collapse
Affiliation(s)
- Chandrasekhar Bhaskaran Nair
- bigtec Private Limited, 2nd Floor, Golden Heights, 59th C Cross, 4th M Block, Rajajinagar, Bangalore, 560 010, Karnataka, India
- School of Bio Sciences and Technology, School of Advanced Sciences VIT University, Vellore, Tamil Nadu, 632014, India
| | - Jagannath Manjula
- bigtec Private Limited, 2nd Floor, Golden Heights, 59th C Cross, 4th M Block, Rajajinagar, Bangalore, 560 010, Karnataka, India
| | - Pradeep Annamalai Subramani
- National Institute of Malaria Research, ICMR Complex, Poojanahalli, Kannamangala Post, Devanahalli, Bangalore, 562 110, Karnataka, India
| | - Prakash B. Nagendrappa
- Institute of Trans-disciplinary Health Sciences and Technology (IHST), FRLHT, 74/2, Jarakabande Kaval, Attur post, Via Yelahanka, Bangalore, 560 106, Karnataka, India
| | - Mulakkapurath Narayanan Manoj
- bigtec Private Limited, 2nd Floor, Golden Heights, 59th C Cross, 4th M Block, Rajajinagar, Bangalore, 560 010, Karnataka, India
| | - Sukriti Malpani
- bigtec Private Limited, 2nd Floor, Golden Heights, 59th C Cross, 4th M Block, Rajajinagar, Bangalore, 560 010, Karnataka, India
| | - Phani Kumar Pullela
- bigtec Private Limited, 2nd Floor, Golden Heights, 59th C Cross, 4th M Block, Rajajinagar, Bangalore, 560 010, Karnataka, India
| | - Pillarisetti Venkata Subbarao
- bigtec Private Limited, 2nd Floor, Golden Heights, 59th C Cross, 4th M Block, Rajajinagar, Bangalore, 560 010, Karnataka, India
| | - Siva Ramamoorthy
- School of Bio Sciences and Technology, School of Advanced Sciences VIT University, Vellore, Tamil Nadu, 632014, India
| | - Susanta K. Ghosh
- National Institute of Malaria Research, ICMR Complex, Poojanahalli, Kannamangala Post, Devanahalli, Bangalore, 562 110, Karnataka, India
- * E-mail:
| |
Collapse
|
8
|
Pavone M, Malpani S, Dyson M, Monsivais D, Mittal N, Bulun S. Differences in retinoid uptake and metabolism alters paracrine signaling in endometriosis. Fertil Steril 2013. [DOI: 10.1016/j.fertnstert.2013.07.196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Ma JJ, Monsivais D, Dyson MT, Coon JS, Malpani S, Ono M, Zhao H, Xin H, Pavone ME, Kim JJ, Chakravarti D, Bulun SE. Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival. Discov Oncol 2013; 4:358-70. [PMID: 23943160 DOI: 10.1007/s12672-013-0157-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Accepted: 07/30/2013] [Indexed: 12/22/2022] Open
Abstract
Endometrial cancer is the fourth most common malignancy among women and is a major cause of morbidity contributing to approximately 8,200 annual deaths in the USA. Despite advances to the understanding of endometrial cancer, novel interventions for the disease are necessary given that many tumors become refractory to therapy. As a strategy to identify novel therapies for endometrial carcinoma, in this study, we examined the contribution of the peroxisome proliferator-activated receptor β/δ (PPARβ/δ) to endometrial cancer cell proliferation and apoptosis. We found that when activated with the highly selective PPARβ/δ agonists, GW0742 and GW501516, PPARβ/δ inhibited the proliferation and markedly induced the apoptosis of three endometrial cancer cell lines. The specificity of the PPARβ/δ-induced effects on cell proliferation and apoptosis was demonstrated using PPARβ/δ-selective antagonists and PPARβ/δ small interfering RNA in combination with PPARβ/δ-selective agonists. Furthermore, we showed that PPARβ/δ activation increased phosphatase and tensin homolog expression, which led to protein kinase B (AKT) and glycogen synthase kinase-3β (GSK3β) dephosphorylation, and increased β-catenin phosphorylation associated with its degradation. Overall, our data suggest that the antitumorigenic effect of PPARβ/δ activation in endometrial cancer is mediated through the negative regulation of the AKT/GSK3β/β-catenin pathway. These findings warrant further investigation of PPARβ/δ as a therapeutic target in endometrial cancer.
Collapse
Affiliation(s)
- J J Ma
- Division of Reproductive Biology Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, 250 E. Superior Street, Suite 3-2306, Chicago, IL, 60611-02914, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Pavone M, Malpani S, Dyson M, Monsivais D, Bulun S. Fenretinide as a novel treatment for endometriosis. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
11
|
Pavone M, Malpani S, Dyson M, Monsivais D, Kakinuma T, Bulun S. Differences in retinoid uptake and metabolism causes altered paracrine signaling in endometriosis. Fertil Steril 2012. [DOI: 10.1016/j.fertnstert.2012.07.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Zoorob RJ, Larzelere MM, Malpani S, Zoorob R. Use and perceptions of antibiotics for upper respiratory infections among college students. J Fam Pract 2001; 50:32-37. [PMID: 11195478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
BACKGROUND Upper respiratory infections (URIs) are mainly viral in nature, rendering antibiotics ineffective. Little is known about what college students believe concerning the effectiveness of antibiotics as a treatment for URIs. METHODS Students (n=425) on 3 college campuses were surveyed using a survey describing 3 variations in presentation of an uncomplicated URI. Participants were questioned about their likelihood of using a variety of treatments for the URI and about their likelihood of seeking a physician's care. RESULTS The percentage of students endorsing antibiotic use differed significantly by symptom complex. Likelihood of seeking medical care also differed significantly across symptom groups, with greater endorsement in the discolored nasal discharge and low-grade fever scenarios. Stepwise multiple regression analysis revealed that belief in antibiotic effectiveness for cold symptoms decreased with tic and Therapeutic increasing years of higher education. Likelihood of antibiotic use across different scenarios increased with age. Likelihood of seeking care across different scenarios was related to type of health insurance and belief in antibiotic effectiveness. CONCLUSIONS Undergraduate college students show poor recognition of typical presentations of the common cold and have misconceptions about effective treatment. Although increasing years of college correlated with decreasing belief in antibiotics' effectiveness for a cold, more health education at the college level is recommended.
Collapse
Affiliation(s)
- R J Zoorob
- Department of Family Medicine, LSU School of Medicine, Kenner, USA.
| | | | | | | |
Collapse
|
13
|
Bhargava P, Mathur SK, Mathur DK, Malpani S, Goel S, Agarwal US, Bhargava RK. Acrochordon, diabetes and associations. Indian J Dermatol Venereol Leprol 1996; 62:226-228. [PMID: 20948060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A study of clinical profile of acrochordons was carried out in 100 patients. Their association with diabetes mellitus and other disorders was studied. Acrochordons were found to be closely associated with pseudo-acanthosis nigricans, seborrhoeic keratosis, obesity and non-insulin dependent diabetes mellitus.
Collapse
Affiliation(s)
- P Bhargava
- Departments of Dermatology, SMS Medical College, Jaipur, India
| | | | | | | | | | | | | |
Collapse
|
14
|
Balachandran C, Malpani S, Srinivas CR. Ciprofloxacin therapy in chronic folliculitis of legs. Indian J Dermatol Venereol Leprol 1995; 61:212-213. [PMID: 20952957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The efficacy of ciprofloxacin was evaluated in 25 patients with chronic folliculitis of legs in a double-blind cross over study. Though ciprofloxacin was found to be far more effective than the placebo the average remission time was only 44.5 days.
Collapse
Affiliation(s)
- C Balachandran
- Department of Skin and STD, Kasturba Medical College, Manipal - 576119, India
| | | | | |
Collapse
|
15
|
Agarwal US, Malpani S, Mathur NK. Annular lesions in congenital syphilis. Genitourin Med 1992; 68:195-6. [PMID: 1607199 PMCID: PMC1194860 DOI: 10.1136/sti.68.3.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|